Analysts’ Recommendations for Eli Lilly in January



Share price movements

Eli Lilly and Company (LLY) is a leading large pharmaceutical company with a total market cap of $117.91 billion.

On January 3, the company closed at $111.31, 3.11% lower than its previous day’s closing price. The company’s 52-week high is $119.84, while its 52-week low is $73.69. Currently, the stock is trading at a discount of 7.12% to its 52-week high and a premium of 51.05% to its 52-week low.

Based on its closing price on January 3, the company had reported returns of 0.20% in the last week, -6.18% in the last month, and 3.10% in the last quarter. Eli Lilly had also reported returns of 28.67% in the last half year, 31.45% in the last year, and -3.81% year-to-date.

On December 31, 2018, Eli Lilly reported a gain of 40.08% compared to its price on January 2, 2018, significantly higher than the 24.08% gain reported by Pfizer (PFE) in the same timeframe.

Article continues below advertisement

Analysts’ recommendations and target prices

Analysts’ 12-month consensus recommendation for Eli Lilly as of January 3 is a “buy.” The 12-month consensus target price for the company is $118.19, 6.18% higher than its closing price on January 3. The highest target price estimate for the company is $136, and the lowest target price is $93.

Of the 17 analysts covering Eli Lilly on January 3, two analysts rated the stock as a “strong buy,” six rated the stock as a “buy,” and nine rated the stock as a “hold.”

In the next article, we’ll compare the revenue growth prospects of Pfizer and Eli Lilly in greater detail.


More From Market Realist